File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Book Chapter: In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia
| Title | In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia |
|---|---|
| Authors | |
| Issue Date | 28-Sep-2023 |
| Publisher | Springer Nature Singapore |
| Abstract | Acute myeloid leukaemia (AML) is an aggressive, heterogenous, and age-related haematological malignancy with dismal prognosis. Conventional therapy for AML consists of frontline induction therapy with cytarabine infusion for 7 days and administration of anthracyclines, most commonly daunorubicin, for 3 days (7 + 3), followed by subsequent consolidation with chemotherapy or allogeneic haematopoietic stem cell transplant (HSCT) for high-risk disease. However, the age-related nature of AML implies that a significant portion of patients are unfit for such intensive regimens and can only be put on palliative treatment. Increasing emphasis is being put on maximizing specificities and potencies of novel agents while minimizing treatment-related toxicities, entailing a future of personalized-therapy in AML. This chapter reviews recently approved agents and agents still in the pipeline for the treatment of AML both in the frontline and the relapsed/refractory setting. |
| Persistent Identifier | http://hdl.handle.net/10722/341836 |
| ISBN |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gill, Harinder | - |
| dc.contributor.author | Yip, Amber | - |
| dc.date.accessioned | 2024-03-26T05:37:34Z | - |
| dc.date.available | 2024-03-26T05:37:34Z | - |
| dc.date.issued | 2023-09-28 | - |
| dc.identifier.isbn | 9789819938094 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/341836 | - |
| dc.description.abstract | <p>Acute myeloid leukaemia (AML) is an aggressive, heterogenous, and age-related haematological malignancy with dismal prognosis. Conventional therapy for AML consists of frontline induction therapy with cytarabine infusion for 7 days and administration of anthracyclines, most commonly daunorubicin, for 3 days (7 + 3), followed by subsequent consolidation with chemotherapy or allogeneic haematopoietic stem cell transplant (HSCT) for high-risk disease. However, the age-related nature of AML implies that a significant portion of patients are unfit for such intensive regimens and can only be put on palliative treatment. Increasing emphasis is being put on maximizing specificities and potencies of novel agents while minimizing treatment-related toxicities, entailing a future of personalized-therapy in AML. This chapter reviews recently approved agents and agents still in the pipeline for the treatment of AML both in the frontline and the relapsed/refractory setting.<br></p> | - |
| dc.language | eng | - |
| dc.publisher | Springer Nature Singapore | - |
| dc.relation.ispartof | Pathogenesis and Treatment of Leukemia | - |
| dc.title | In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia | - |
| dc.type | Book_Chapter | - |
| dc.identifier.doi | 10.1007/978-981-99-3810-0_16 | - |
| dc.identifier.eisbn | 9789819938100 | - |